| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |